Impact of lymph node metastases on outcome following treatment with sorafenib in patients with hepatocellular carcinoma (HCC): Subset analysis from the phase III SHARP trial

被引：0
|
作者：
Raoul, J.
Craxi, A.
Porta, C.
Lentini, G.
Nadel, A.
Voliotis, D.
Bruix, J.
Llovet, J. M.
机构：
[1] Ctr Eugene Marquis, Rennes, France
[2] Azienda Osped Univ, Palermo, Italy
[3] San Matteo Univ Hosp, IRCCS, Pavia, Italy
[4] Bayer Vital GmbH, Leverkusen, Germany
[5] Bayer HealthCare Pharmaceut, Montville, NJ USA
[6] Hosp Clin Barcelona, Barcelona, Spain
[7] Mt Sinai Sch Med, New York, NY USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2009年 / 27卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e15547
引用
收藏
页数：2
相关论文
共 50 条
  • [21] Treatment outcome of palliative radiotherapy for lymph node metastasis from hepatocellular carcinoma
    Chie, E.
    Kim, K.
    Kim, W.
    Yoon, J.
    Ha, S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2008, 72 (01): : S268 - S268
  • [22] Phase II trial of sorafenib (S) and capecitabine (C) for hepatocellular carcinoma (HCC) in cirrhotic patients (pts).
    Rojas-Hernandez, Cristhiam Mauricio
    Patt, Yehuda Z.
    Fekrazad, M. Houman
    Steinberg, Kim A.
    Roach, Mary
    Lee, Fa-Chyi
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [23] Phase II trial of tepotinib vs sorafenib in Asian patients (pts) with advanced hepatocellular carcinoma (HCC)
    Ryoo, B-Y.
    Ren, Z.
    Kim, T-Y.
    Pan, H.
    Rau, K-M.
    Choi, H. J.
    Park, J-W.
    Kim, J. H.
    Yen, C-J.
    Kim, B-H.
    Zhou, D.
    Straub, J.
    Zhao, C.
    Qin, S.
    ANNALS OF ONCOLOGY, 2018, 29
  • [24] Complete response to short-term sorafenib treatment alone for hepatocellular carcinoma with bone, lymph node, and peritoneum metastases
    Nakano, Norihito
    Kawaoka, Tomokazu
    Aikata, Hiroshi
    Honda, Fumi
    Nakamura, Yuki
    Morio, Kei
    Hatooka, Masahiro
    Fukuhara, Takayuki
    Kobayashi, Tomoki
    Hiramatsu, Akira
    Imamura, Michio
    Kawakami, Yoshiiku
    Takahashi, Shoichi
    Chayama, Kazuaki
    HEPATOLOGY RESEARCH, 2016, 46 (13) : 1402 - 1408
  • [25] REFLECT—a phase 3 trial comparing efficacy and safety of lenvatinib to sorafenib for the treatment of unresectable hepatocellular carcinoma: an analysis of Japanese subset
    Tatsuya Yamashita
    Masatoshi Kudo
    Kenji Ikeda
    Namiki Izumi
    Ryosuke Tateishi
    Masafumi Ikeda
    Hiroshi Aikata
    Yasunori Kawaguchi
    Yoshiyuki Wada
    Kazushi Numata
    Yoshitaka Inaba
    Ryoko Kuromatsu
    Masahiro Kobayashi
    Takuji Okusaka
    Toshiyuki Tamai
    Chifumi Kitamura
    Kenichi Saito
    Katsuya Haruna
    Kiwamu Okita
    Hiromitsu Kumada
    Journal of Gastroenterology, 2020, 55 : 113 - 122
  • [26] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance)
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Lammers, Philip Edward
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby B.
    Balletti, Jennifer
    Harding, James J.
    Howard, Lawrence Schwartz
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [27] Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance).
    Abou-Alfa, Ghassan K.
    Niedzwieski, Donna
    Knox, Jennifer J.
    Kaubisch, Andreas
    Posey, James
    Tan, Benjamin R.
    Kavan, Petr
    Goel, Rakesh
    Murray, John J.
    Bekaii-Saab, Tanios S.
    Tam, Vincent Channing
    Rajdev, Lakshmi
    Kelley, Robin Kate
    Siegel, Abby
    Balletti, Jennifer
    Harding, James J.
    Schwartz, Lawrence Howard
    Goldberg, Richard M.
    Bertagnolli, Monica M.
    Venook, Alan P.
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (04)
  • [28] Linifanib Versus Sorafenib in Patients With Advanced Hepatocellular Carcinoma: Results of a Randomized Phase III Trial
    Cainap, Calin
    Qin, Shukui
    Huang, Wen-Tsung
    Chung, Ik Joo
    Pan, Hongming
    Cheng, Ying
    Kudo, Masatoshi
    Kang, Yoon-Koo
    Chen, Pei-Jer
    Toh, Han-Chong
    Gorbunova, Vera
    Eskens, Ferry A. L. M.
    Qian, Jiang
    McKee, Mark D.
    Ricker, Justin L.
    Carlson, Dawn M.
    El-Nowiem, Saied
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (02) : 172 - U77
  • [29] RESORCE: An ongoing randomized, double-blind, phase III trial of regorafenib (REG) in patients with hepatocellular carcinoma (HCC) progressing on sorafenib (SOR).
    Bruix, Jordi
    Finn, Richard S.
    Kudo, Masatashi
    Llovet, Josep M.
    Qin, Shukui
    Le Berre, Marie-Aude
    Wagner, Andrea
    Chang, Ann-Lii
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [30] Randomized phase III trial of sorafenib versus placebo in Asian patients with advanced hepatocellular carcinoma
    Cheng, A.
    Kang, Y.
    Chen, Z.
    Tsao, C.
    Qin, S.
    Kim, J.
    Burock, K.
    Zou, J.
    Voliotis, D.
    Guan, Z. Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
12345